Cargando…
Clinical utility of pharmacogenomics in the management of hepatitis C
Hepatitis C virus (HCV) was identified for the first time more than 20 years ago. Since then, several studies have highlighted the complicated aspects of this viral infection in relation to its worldwide prevalence, its clinical presentation, and its therapeutic response. Recently, two landmark scie...
Autores principales: | Trinks, Julieta, Hulaniuk, María Laura, Redal, María Ana, Flichman, Diego |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4222698/ https://www.ncbi.nlm.nih.gov/pubmed/25382982 http://dx.doi.org/10.2147/PGPM.S52624 |
Ejemplares similares
-
Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals
por: Trinks, Julieta, et al.
Publicado: (2017) -
Influence of ethnicity on the distribution of genetic polymorphisms associated with risk of chronic liver disease in South American populations
por: Pontoriero, Ana Cecilia, et al.
Publicado: (2015) -
Prevalence and Factors Related to Natural Resistance-Associated Substitutions to Direct-Acting Antivirals in Patients with Genotype 1 Hepatitis C Virus Infection
por: Esposito, Isabella, et al.
Publicado: (2018) -
State of Art of Cancer Pharmacogenomics in Latin American Populations
por: López-Cortés, Andrés, et al.
Publicado: (2017) -
Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions
por: Ridruejo, Ezequiel, et al.
Publicado: (2021)